Knight Therapeutics Signs an Exclusive License Agreement with Puma Biotechnology for its Nerlynx (neratinib)

 Knight Therapeutics Signs an Exclusive License Agreement with Puma Biotechnology for its Nerlynx (neratinib)

Knight Therapeutics Signs an Exclusive License Agreement with Puma Biotechnology for its Nerlynx (neratinib)

Shots:
  • Puma to receive upfront, milestones up to $7.2M and royalties on sales in Canada. Knight to get exclusive commercialization rights for Nerlynx and will also be responsible for its regulatory approvals in Canada
  • In July, 2018 Puma has filled Nerlyn’s NDA to Health Canada for the treatment of early stage HER2-overexpressed/amplified breast cancer following adjuvant trastuzumab-based therapy in adults
  •  Nerlynx (neratinib) is a tyrosine kinase inhibitor anticancer drug and has received the US FDA approval in July 2017, for early stage HER2-positive breast cancer following adjuvant trastuzumab-based therapy in adults
Click here to read full press release/ article | Ref: Puma Biotechnology | Image: ValueWalk

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post